157 related articles for article (PubMed ID: 10794815)
21. Spinal antinociceptive effects of [D-Ala2]deltorphin II, a novel and highly selective delta-opioid receptor agonist.
Improta G; Broccardo M
Peptides; 1992; 13(6):1123-6. PubMed ID: 1362979
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the antinociceptive effects of new [D-Arg2]-dermorphin tetrapeptide analogs and morphine in mice.
Chaki K; Sakurada S; Sakurada T; Sato T; Kawamura S; Kisara K; Watanabe H; Suzuki K
Pharmacol Biochem Behav; 1988 Oct; 31(2):439-44. PubMed ID: 2907624
[TBL] [Abstract][Full Text] [Related]
23. Endomorphin analogues containing D-Pro2 discriminate different mu-opioid receptor mediated antinociception in mice.
Sakurada S; Watanabe H; Hayashi T; Yuhki M; Fujimura T; Murayama K; Sakurada C; Sakurada T
Br J Pharmacol; 2002 Dec; 137(8):1143-6. PubMed ID: 12466222
[TBL] [Abstract][Full Text] [Related]
24. Meptazinol: unusual in vivo opioid receptor activity at supraspinal and spinal sites.
Dray A; Nunan L; Wire W
Neuropharmacology; 1986 Apr; 25(4):343-9. PubMed ID: 3012396
[TBL] [Abstract][Full Text] [Related]
25. Supraspinal antinociception produced by [D-Met2]-FMRFamide in mice.
Raffa RB; Connelly CD
Neuropeptides; 1992 Jul; 22(3):195-203. PubMed ID: 1331846
[TBL] [Abstract][Full Text] [Related]
26. Prolonged in vivo antagonism of central mu- and delta-opioid receptor activity by beta-funal trexamine.
Dray A; Nunan L; Wire W
Life Sci; 1985 Apr; 36(14):1353-8. PubMed ID: 2984501
[TBL] [Abstract][Full Text] [Related]
27. Cross-tolerance studies in the spinal cord of beta-FNA-treated mice provides further evidence for delta opioid receptor subtypes.
Sofuoglu M; Portoghese PS; Takemori AE
Life Sci; 1991; 49(19):PL153-6. PubMed ID: 1658509
[TBL] [Abstract][Full Text] [Related]
28. Naloxonazine and opioid-induced inhibition of reflex urinary bladder contractions.
Dray A; Nunan L; Wire W
Neuropharmacology; 1987 Jan; 26(1):67-74. PubMed ID: 3031536
[TBL] [Abstract][Full Text] [Related]
29. Differential modulation of alpha 2-adrenergic and mu-opioid spinal antinociception by neuropeptide FF.
Kontinen VK; Kalso EA
Peptides; 1995; 16(5):973-7. PubMed ID: 7479344
[TBL] [Abstract][Full Text] [Related]
30. N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers.
Yekkirala AS; Lunzer MM; McCurdy CR; Powers MD; Kalyuzhny AE; Roerig SC; Portoghese PS
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5098-103. PubMed ID: 21385944
[TBL] [Abstract][Full Text] [Related]
31. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
[TBL] [Abstract][Full Text] [Related]
32. Determination of the relative involvement of mu-opioid receptors in opioid-induced depression of respiratory rate by use of beta-funaltrexamine.
Ward SJ; Takemori AE
Eur J Pharmacol; 1983 Jan; 87(1):1-6. PubMed ID: 6301847
[TBL] [Abstract][Full Text] [Related]
33. Novel met-enkephalin analogue: a potent systemic mu agonist antinociceptive agent.
Nath C; Patnaik GK; Haq W; Mathur KB; Srimal RC; Dhawan BN; Porreca F
Pharmacol Res; 1995 May; 31(5):269-73. PubMed ID: 7479523
[TBL] [Abstract][Full Text] [Related]
34. CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist.
Hough LB; Nalwalk JW; Phillips JG; Kern B; Shan Z; Wentland MP; de Esch IJ; Janssen E; Barr T; Stadel R
Neuropharmacology; 2007 Apr; 52(5):1244-55. PubMed ID: 17336343
[TBL] [Abstract][Full Text] [Related]
35. μ-Opioid Receptor Activation at the Dorsal Reticular Nucleus Shifts Diffuse Noxious Inhibitory Controls to Hyperalgesia in Chronic Joint Pain in Male Rats.
Pereira-Silva R; Teixeira-Pinto A; Neto FL; Martins I
Anesthesiology; 2024 Jun; 140(6):1176-1191. PubMed ID: 38381969
[TBL] [Abstract][Full Text] [Related]
36. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting mu-opioid receptor antagonist devoid of agonist properties.
Jiang Q; Sebastian A; Archer S; Bidlack JM
Eur J Pharmacol; 1993 Jan; 230(1):129-30. PubMed ID: 7679076
[TBL] [Abstract][Full Text] [Related]
37. Antagonism of morphine analgesia by intracerebroventricular naloxonazine.
Simone DA; Bodnar RJ; Portzline T; Pasternak GW
Pharmacol Biochem Behav; 1986 Jun; 24(6):1721-7. PubMed ID: 3016762
[TBL] [Abstract][Full Text] [Related]
38. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.
Daniels DJ; Lenard NR; Etienne CL; Law PY; Roerig SC; Portoghese PS
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19208-13. PubMed ID: 16365317
[TBL] [Abstract][Full Text] [Related]
39. Coincident Regulation of PLC
Sanchez GA; Jutkiewicz EM; Ingram S; Smrcka AV
Mol Pharmacol; 2022 Dec; 102(6):269-279. PubMed ID: 36116788
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the antinociceptive effect between D-Arg containing dipeptides and tetrapeptides in mice.
Sato T; Sakurada S; Sakurada T; Furuta S; Nakata N; Kisara K; Sasaki Y; Suzuki K
Neuropeptides; 1984 Jun; 4(4):269-79. PubMed ID: 6548000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
